PLIVA d.d. announced today that an agreement has been signed with Novartis’ generics division, Sandoz, for the purchase of its Spanish subsidiary Uso Racional S.L for a total cash consideration of EUR 21.5m.

PLIVA d.d. (LSE: PLVD) today announced a deal in which it has reached agreement with GlaxoSmithKline (GSK) for the purchase of PLIVA – Istraživački Institut d.o.o. (PLIVA – Research Institute Ltd.), PLIVA’s proprietary R&D arm renowned for its research into macrolides, in Zagreb, Croatia. In May 2005, PLIVA announced its strategic intent to completely focus on its generics operations and exit the proprietary business. Following the divestments of the majority of PLIVA’s US proprietary business and Research Institute in Zagreb, PLIVA has now successfully completed its strategic objective of exiting the proprietary segment.

PLIVA d.d. announced today that its German subsidiary AWD.pharma GmbH & Co. KG signed an agreement with the Menarini Group (“Menarini”) of Italy, for the divestment of its manufacturing plant in Dresden, Germany. The sale of the German facility reflects a key step in the process of optimizing PLIVA’s manufacturing asset base and consolidation of production, which was announced at the end of 2004.

PLIVA d.d. announced today that following an in-depth strategic review and evaluation of its core activities and approval from its Supervisory Board, it has decided to exit the proprietary segment and focus operations on its generics business.

Please find PLIVA's Q1 Results attached in pdf format.

PLIVA d.d. announced today that its affiliates PAM Kft. and PLIVA CROATIA Ltd. have entered into a strategic collaboration with Mayne Pharma, a leading international hospital generics company, for the development, supply and marketing of PLIVA’s two most advanced followon biologics programs, erythropoietin (EPO) and granulocyte colony stimulating factor (“G-CSF”).

On 01 December 2004 PLIVA launched its new corporate website.

H1 2004 Results announced.